The therapeutic potential of GLP‐1 receptor biased agonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments for type 2 diabetes as they stimulate insulin release and promote weight loss through appetite suppression. Their main side effect is nausea. All approved GLP‐1 agonists are full agonists across multiple signalling pathways. However, selective engagement with specific intracellular effectors, or biased agonism, has been touted as a means to improve GLP‐1 agonists therapeutic efficacy. In this review, I critically examine how GLP‐1 receptor‐mediated intracellular signalling is linked to physiological responses and discuss the implications of recent studies investigating the metabolic effects of biased GLP‐1 agonists. Overall, there is little conclusive evidence that beneficial and adverse effects of GLP‐1 agonists are attributable to distinct, nonoverlapping signalling pathways. Instead, G protein‐biased GLP‐1 agonists appear to achieve enhanced anti‐hyperglycaemic efficacy by avoiding GLP‐1 receptor desensitisation and downregulation, partly via reduced β‐arrestin recruitment. This effect seemingly applies more to insulin release than to appetite regulation and nausea, possible reasons for which are discussed. At present, most evidence derives from cellular and animal studies, and more human data are required to determine whether this approach represents a genuine therapeutic advance. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 2×
“GLP-1 agonist treat- ment improves glycaemia, aids weight loss, improves cardiovascular, renal and limb outcomes, and leads to a reduction in all-cause mortality in type 2 diabetes (Kristensen et al., 2019; Zheng et al., 2018).”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“2022;179:492–510.wileyonlinelibrary.com/journal/bph also effective in causing weight loss in people without type 2 diabetes (Davies et al., 2015) and for non-alcoholic fatty liver disease (Armstrong et al., 2016).”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“Previous concerns have been raised about the potential for GLP-1 agonists to cause pancreatitis (Garber et al., 2009), although this has not been confirmed in recent analyses (Storgaard et al., 2017).”
ResultThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 2×
“Early work confirmed GLP-1 stimulates cAMP production in islet cell lines and the brain (Drucker et al., 1987; Shimizu et al., 1987).”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Initial descriptions of tirzepatide showed similar GIPR potency to native GIP but fivefold reduced potency for GLP-1 receptor (Coskun et al., 2018).”
BackgroundFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Research works printed but not linked: 105
- 10.1111/bph.14748 · DOI · Paper page
- 10.1111/bph.14751 · DOI · Paper page
- 10.1016/S0140-6736(15)00803-X · DOI · Paper page
- 10.1038/s41467-020-14309-w · DOI · Paper page
- Avet C. Mancini A. Breton B. Le Gouill C. Hauser A. S. Normand C. Kobayashi H. Gross F. Hogue M. Lukasheva V. &Morissette S.(2020).Selectivity Landscape of 100 Therapeutically Relevant GPCR Profiled by an Effector Translocation‐Based BRET Platform. bioRxiv48: 2020.04.20.052027. · DOI
- 10.1172/JCI126309 · DOI · Paper page
- 10.1002/path.5056 · DOI · Paper page
- 10.3390/biology9120473 · DOI
- 10.1126/scitranslmed.aan0972 · DOI · Paper page
- 10.2337/diabetes.52.4.974 · DOI · Paper page
- 10.1371/journal.pbio.3000097 · DOI · Paper page
- 10.1371/journal.pbio.1000172 · DOI · Paper page
- 10.1038/nm.3997 · DOI · Paper page
- 10.1002/cbic.201900300 · DOI
- 10.1038/s41596-018-0028-3 · DOI · Paper page
- 10.1124/jpet.110.166009 · DOI
- 10.1016/j.molmet.2015.07.008 · DOI · Paper page
- 10.1083/jcb.131.1.69 · DOI · Paper page
- 10.1016/j.bcp.2020.114150 · DOI · Paper page
- 10.4161/cl.23967 · DOI · Paper page
- 10.3390/ijms21218404 · DOI · Paper page
- 10.1016/0026-0495(94)90132-5 · DOI
- 10.1016/j.bcp.2018.09.003 · DOI
- 10.1039/C9SC02079A · DOI
- Fridolf T., 1991, GLP‐1(7‐36) amide stimulates insulin secretion in rat islets: Studies on the mode of action, Diabetes Research, 16, 185
- 10.3389/fphys.2020.00555 · DOI · Paper page
- 10.1016/j.bcp.2016.03.003 · DOI
- 10.1126/scisignal.aaz3140 · DOI · Paper page
- 10.1016/j.tips.2020.09.009 · DOI · Paper page
- 10.1016/j.molmet.2017.08.002 · DOI · Paper page
- 10.1152/ajpgi.1989.257.3.G397 · DOI · Paper page
- Griffith D. A. Edmonds D. J. Fortin J. P. Kalgutkar A. S. Kuzmiski J. B. Loria P. M. Saxena A. R. Bagley S. W. Buckeridge C. Curto J. M. &Derksen D. R.(2020).A small‐molecule oral agonist of the human glucagon‐like peptide‐1 receptor. bioRxiv261: 2020.09.29.319483. · DOI
- 10.1038/s41467-017-02661-3 · DOI · Paper page
- 10.1016/j.bcp.2017.03.018 · DOI · Paper page
- 10.1021/jacs.6b08323 · DOI
- 10.1016/j.cmet.2011.02.001 · DOI · Paper page
- 10.1124/jpet.109.158519 · DOI
- 10.1016/j.peptides.2017.12.013 · DOI
- 10.1038/s41467-018-03941-2 · DOI · Paper page
- 10.1074/jbc.ra120.016334 · DOI · Paper page
- 10.1124/jpet.107.120006 · DOI
- 10.1113/jphysiol.2007.143818 · DOI · Paper page
- 10.1074/jbc.M108378200 · DOI · Paper page
- 10.1055/s-0030-1249035 · DOI
- 10.1038/srep41085 · DOI · Paper page
- 10.1124/mol.117.111187 · DOI
- 10.1021/cn200111m · DOI · Paper page
- 10.1111/j.1476-5381.1984.tb10753.x · DOI
- 10.1038/ncomms10842 · DOI · Paper page
- 10.1111/bph.15004 · DOI · Paper page
- 10.1124/mol.110.065664 · DOI · Paper page
- 10.1152/ajpendo.00551.2012 · DOI · Paper page
- 10.1073/pnas.94.26.14942 · DOI · Paper page
- 10.1021/jacs.9b05365 · DOI
- 10.1038/nature25773 · DOI · Paper page
- 10.1016/j.neuron.2017.09.042 · DOI · Paper page
- 10.1038/382083a0 · DOI · Paper page
- 10.1016/j.molmet.2020.100991 · DOI · Paper page
- 10.1073/pnas.041604898 · DOI · Paper page
- 10.1126/scisignal.aat7650 · DOI · Paper page
- 10.1016/j.coemr.2020.07.003 · DOI
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
- 10.1016/j.molmet.2021.101181 · DOI · Paper page
- 10.1172/JCI140046 · DOI · Paper page
- 10.1021/acssensors.9b01414 · DOI
- 10.1038/srep44247 · DOI
- 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
- 10.1016/j.ejphar.2020.173706 · DOI
- 10.1111/bph.15134 · DOI · Paper page
- 10.1016/j.ejmech.2016.10.044 · DOI
- 10.1021/acscentsci.7b00237 · DOI
- 10.1074/jbc.M109.067207 · DOI · Paper page
- 10.1124/jpet.105.087254 · DOI · Paper page
- 10.1007/s00125-013-3130-7 · DOI
- 10.2337/dc20-0190 · DOI · Paper page
- 10.1074/jbc.M114.592436 · DOI · Paper page
- 10.1186/s12575-019-0116-y · DOI
- 10.1210/endo-121-3-1076 · DOI · Paper page
- 10.1111/jdi.12900 · DOI
- 10.1172/JCI72434 · DOI · Paper page
- 10.2337/diabetes.49.7.1156 · DOI · Paper page
- 10.2337/db12-1394 · DOI · Paper page
- 10.1016/j.bcp.2014.10.015 · DOI
- 10.1111/dom.13494 · DOI · Paper page
- 10.1042/bj20021288 · DOI · Paper page
- 10.1021/acsptsci.0c00193 · DOI
- 10.1074/jbc.RA118.001975 · DOI · Paper page
- 10.1016/j.neuroscience.2012.09.025 · DOI
- 10.1111/bph.12716 · DOI · Paper page
- 10.1038/s41598-017-03486-2 · DOI
- 10.1042/bj3100203 · DOI · Paper page
- 10.1038/s41580-018-0049-3 · DOI · Paper page
- 10.1016/j.cell.2016.05.023 · DOI · Paper page
- 10.1124/jpet.110.176362 · DOI
- 10.1073/pnas.0704796104 · DOI · Paper page
- 10.1016/j.bcp.2020.114001 · DOI · Paper page
- 10.1016/j.cmet.2006.10.001 · DOI · Paper page
- 10.1016/0167-0115(93)90137-W · DOI
- 10.1038/ncomms9918 · DOI · Paper page
- 10.1016/j.ydbio.2009.12.042 · DOI
- 10.1016/j.molcel.2020.09.020 · DOI · Paper page
- 10.1038/s41586-019-1902-z · DOI · Paper page
- 10.1001/jama.2018.3024 · DOI · Paper page
- 10.1038/srep26859 · DOI · Paper page
- 10.1038/ncomms14295 · DOI · Paper page
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“One prevailing theory is that tirzepatide is an imbalanced and biased GLP-1 RA with very low ef fi cacy for recruitment of β -arrestin, whilst is acting as an unbiased GIP agonist with full ef fi cacy for β -arrestin recruitment [51, 52].”
Emerging Role of cAMP/AMPK Signaling
Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“While cursory efforts have been devoted to characterizing the structure activity relationship responsible for this signaling profile at the GLP-1R [65], the structural and sequence determinants of biased agonism at GIPR and GcgR are largely unknown, and thus would add another level of complexity to the structuree acti…”
BackgroundHorn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
Gao, W., Liu, L., Huh, E., Gbahou, F., Cecon, E., Oshima, M., Houzé, L., Katsonis, P., Hegron, A., Fan, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00889-6 · Cited by 56
“This observation supports the concept that β-arr-dependent internalization limits the action of GLP1R activation on insulin secretion and suggests that carriers of LoF variants not associated with β-arr could benefit from Gs-biased ligands 24 .”
Background
Metadata
- Authors
- Jones, B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-05-20
- Volume
- 179
- Issue
- 4
- Pages
- 492-510
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3156815314
- Cited by
- 98
- References
- 45
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Biotechnology and Biological Sciences Research Council
- European Foundation for the Study of Diabetes
- National Institute for Health Research
- Sunesis
- British Society for Neuroendocrinology
- Society for Endocrinology
- Engineering and Physical Sciences Research Council
- NIHR Imperial Biomedical Research Centre
- Academy of Medical Sciences
- Medical Research Council Canada (MR/R010676/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The therapeutic potential of GLP‐1 receptor biased agonism. https://app.cochat.ai/papers/10.1111/bph.15497
- The paper
- Jones, B. (2022). The therapeutic potential of GLP‐1 receptor biased agonism. British Journal of Pharmacology. https://doi.org/10.1111/bph.15497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.